ClinicalTrials.gg
CompletedNCT03600883Updated Jun 30, 2026

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

A Phase 1/2 interventional study of sotorasib and Anti PD-1/L1 in KRAS p.G12C Mutant Advanced Solid Tumors, sponsored by Amgen. Completed at 133 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
713
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

02

Conditions studied

  • KRAS p.G12C Mutant Advanced Solid Tumors
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women greater than or equal to 18 years old.
  • documented, locally-advanced or with, KRAS p.G12C mutation identified through molecular testing.

Exclusion criteria

Exclusion Criteria

  • Active from non-brain tumors.
  • Myocardial infarction within 6 months of study day 1.
  • Gastrointestinal (GI) tract disease causing the inability to take oral medication.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
713 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Exploration Part 1 monotherapy

    Cohorts with food effect and alternative dosing regimens Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort

    Drug: sotorasib

  • Experimental
    Phase 1 Dose Expansion Part 2 monotherapy

    Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently

    Drug: sotorasib

  • Experimental
    Phase 1 combination arm with sotorasib and anti PD-1/L1

    Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)

    Drug: sotorasib · Drug: Anti PD-1/L1

  • Experimental
    Phase 1 monotherapy treatment naive advanced NSCLC

    Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.

    Drug: sotorasib · Drug: Midazolam

  • Experimental
    Phase 2 monotherapy dose comparison

    Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy

    Drug: sotorasib

  • Experimental
    Phase 1 Does escalation and Expansion monotherapy BID

    BID 2L+solid tumors (fed state)

    Drug: sotorasib

Interventions

  • Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation

  • DrugAnti PD-1/L1

    Administered as an intravenous (IV) infusion

  • Administered as an oral hydrochloride (HCI) syrup

06

What researchers measure

Primary outcomes

  1. Primary: Number of subjects with treatment-emergent adverse events

    Treatment-emergent adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  2. Primary: Number of subjects with treatment-related adverse events

    Treatment-related adverse events will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  3. Primary: Number of subjects with grade ≥3 treatment-emergent adverse events

    Grade ≥3 treatment-emergent adverse events will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  4. Primary: Number of subjects with serious adverse events

    Serious adverse events will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  5. Primary: Number of subjects with adverse events of interest

    Adverse events of interest will be a primary outcome measure in the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  6. Primary: Number of subjects with clinically significant changes in vital signs

    Vital signs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: Baseline to 24 Months

  7. Primary: Number of subjects with clinically significant changes in physical examination results

    Physical examinations will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1

    Time frame: Baseline to 24 Months

  8. Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)

    ECGs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: Baseline to 24 Months

  9. Primary: Number of subjects with clinically significant changes in clinical laboratory values

    Abnormal clinical laboratory values will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: Baseline to 24 Months

  10. Primary: Number of subjects with dose-limiting toxicities (DLTs)

    DLTs will be a primary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 21 Days

  11. Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria

    ORR will be a primary outcome measure in the following group: * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy * Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  12. Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteria

    DOR will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  13. Primary: Disease control as assessed by RECIST 1.1 criteria

    Disease control will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  14. Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria

    Duration of SD will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  15. Primary: Time to response (TTR) as assessed by RECIST 1.1 criteria

    TTR will be a primary outcome measure in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

Secondary outcomes

  1. Secondary: Plasma concentration (Cmax) of sotorasib

    Cmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison

    Time frame: 15 Weeks

  2. Secondary: Plasma concentration (Cmax) of midazolam

    Cmax of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 16 Days

  3. Secondary: Time to achieve Cmax (Tmax) of sotorasib

    Tmax will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 15 Weeks

  4. Secondary: Area under the plasma concentration-time curve (AUC) of sotorasib

    AUC will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 1 monotherapy treatment naïve advanced NSCLC * Phase 2 monotherapy dose comparison

    Time frame: 15 Weeks

  5. Secondary: Area under the plasma concentration-time curve (AUC) of midazolam

    AUC of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 16 Days

  6. Secondary: Clearance of midazolam from the plasma

    Clearance of midazolam from the plasma will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 16 Days

  7. Secondary: Terminal half-life (t1/2) of midazolam

    t1/2 of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group: \- Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 16 Days

  8. Secondary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria

    ORR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1

    Time frame: 24 Months

  9. Secondary: Duration of response (DOR) as assessed by RECIST 1.1 criteria

    DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  10. Secondary: Disease control as assessed by RECIST 1.1 criteria

    DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  11. Secondary: Progression-free survival (PFS) as assessed by RECIST 1.1 criteria

    PFS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  12. Secondary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria

    Duration of SD will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1

    Time frame: 24 Months

  13. Secondary: Depth of response (best percentage change from baseline in lesion sum diameters) as assessed by RECIST 1.1 criteria

    Depth of response will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: Baseline to 24 Months

  14. Secondary: Time to response (TTR) as assessed by RECIST 1.1 criteria

    DOR will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  15. Secondary: Overall survival (OS)

    OS will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy * Phase 2 monotherapy * Phase 1 combination arm with sotorasib and anti PD-1/L1 * Phase 2 monotherapy dose comparison * Phase 1 monotherapy treatment naïve advanced NSCLC

    Time frame: 24 Months

  16. Secondary: sotorasib exposure and QTc interval relationship

    sotorasib exposure and QTc interval relationship will be a secondary outcome measure for the following groups: * Phase 1 Dose Exploration Part 1 monotherapy * Phase 1 Dose Expansion Part 2 monotherapy

    Time frame: 24 Months

  17. Secondary: Progression-free survival (PFS) at 6 months

    PFS at 6 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy

    Time frame: 6 Months

  18. Secondary: Progression-free survival (PFS) at 12 months

    PFS at 12 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy

    Time frame: 12 Months

  19. Secondary: Overall survival (OS) at 12 months

    OS at 12 months will be a secondary outcome measure for the following group: \- Phase 2 monotherapy

    Time frame: 12 Months

  20. Secondary: Number of subjects with treatment-emergent adverse events

    Treatment-emergent adverse events will be a secondary outcome measure for the following group: \- Phase 2 monotherapy

    Time frame: 24 Months

  21. Secondary: Number of subjects with grade ≥3 treatment-emergent adverse events

    Grade ≥3 treatment-emergent adverse events will be a secondary outcome measure for the following group: \- Phase 2 monotherapy

    Time frame: 24 Months

  22. Secondary: Impact of treatment on disease-related symptoms and health related quality of life (HRQOL) as assessed by EORTC QLQ-C30

    Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  23. Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by disease-specific modules Quality-of-Life Questionnaire Lung Cancer Module (QLQ LC13)

    Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  24. Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by non-small cell lung cancer symptom assessment questionnaire (NSCLC SAQ) for NSCLC

    Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  25. Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Severity (PGIS)

    Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  26. Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Change (PGIC) in cough, dyspnea and chest pain for NSCLC

    Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  27. Secondary: Treatment-related symptoms and impact on the subject as assessed by EORTC QLQ-C30

    Treament related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  28. Secondary: Treatment-related symptoms and impact on the subject as assessed by selected questions from the Patient-reported Outcome of the Common Terminology Criteria for Adverse Events (PRO-CTCAE library)

    Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  29. Secondary: Treatment-related symptoms and impact on the subject as assessed by a single item about symptom bother, item GP5 of the Functional Assessment of Cancer Therapy - General (FACT-G)

    Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: 24 Months

  30. Secondary: Change from baseline in physical function as assessed by EORTC QLQ-C30

    Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group: \- Phase 2 monotherapy dose comparison

    Time frame: Baseline to 24 Months

07

Study locations

133 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of California at SF
    San Francisco, California 94115, United States
  • Sarcoma Oncology Research Center LLC
    Santa Monica, California 90403, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
  • University of Florida Health
    Gainesville, Florida 32610, United States
  • AdventHealth Orlando Infusion Center
    Orlando, Florida 32804, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Washington University
    St Louis, Missouri 63110-1093, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Laura and Isaac Perlmutter Cancer Center at New York University Langone
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center, Morris Cancer Clinic
    Durham, North Carolina 27710, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Pittsburgh Medical Center Cancer Pavillion
    Pittsburgh, Pennsylvania 15232, United States
  • Gibbs Cancer Center and Research Institute - Spartanburg
    Spartanburg, South Carolina 29303, United States
  • Vanderbilt University Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Austin Central
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • US Oncology Research Investigational Products Center
    Fairfax, Virginia 22031, United States
  • Virginia Cancer Specialists PC
    Fairfax, Virginia 22031, United States
  • Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Peter MacCallum Cancer Centre
    Parkville, Victoria 3050, Australia
  • Medizinische Universitaet Graz
    Graz, 8036, Austria
  • Medizinische Universitaet Innsbruck
    Innsbruck, 6020, Austria
  • Universitaetsklinikum Krems
    Krems, 3500, Austria
  • Universitaetsklinikum Allgemeines Krankenhaus Wien
    Vienna, 1090, Austria
  • Krankenhaus Nord - Klinik Floridsdorf
    Vienna, 1210, Austria
  • Institut Jules Bordet
    Brussels, B-1070, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse
    Hasselt, 3500, Belgium
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liège, 4000, Belgium
  • AZ Delta Campus Rumbeke
    Roeselare, 8800, Belgium
  • Irmandade da Santa Casa de Misericordia de Porto Alegre, Nucleo de Novos Tratamentos em Cancer
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
    São Paulo, São Paulo 01308-050, Brazil
  • Oncologia Rede D´Or
    São Paulo, São Paulo 04501-000, Brazil
  • Instituto Coi
    Rio de Janeiro, 20231-050, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • London Regional Cancer Program, London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre Hospitalier Intercommunal de Créteil
    Créteil, 94010, France
  • Hopital de la Timone
    Marseille, 13385, France
  • Institut Curie
    Paris, 75005, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
  • Gustave Roussy
    Villejuif, 94805, France
  • Universitatsklinikum Koln
    Cologne, 50937, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Klinikum der Universität München Campus Grosshadern
    München, 81377, Germany
  • Henry Dunant Hospital Center
    Athens, 11526, Greece
  • Metropolitan Hospital
    Athens, 18547, Greece
  • University Hospital of Heraklion
    Heraklion - Crete, 71500, Greece
  • Theagenion Cancer Hospital
    Thessaloniki, 54007, Greece
  • Agios Loukas Clinic
    Thessaloniki, 55236, Greece
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Orszagos Koranyi Pulmonologiai Intezet
    Budapest, 1121, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvár, 7400, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Székesfehérvár, 8000, Hungary
  • Szent Borbala Korhaz
    Tatabánya, 2800, Hungary
  • Tudogyogyintezet Torokbalint
    Törökbálint, 2045, Hungary
  • Aichi Cancer Center
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East
    Kashiwa-shi, Chiba 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, Fukuoka 811-1395, Japan
  • National Hospital Organization Hokkaido Cancer Center
    Sapporo, Hokkaido 003-0804, Japan
  • St Marianna University Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
    Yokohama, Kanagawa 241-8515, Japan
  • Sendai Kousei Hospital
    Sendai, Miyagi 980-0873, Japan
  • Niigata Cancer Center Hospital
    Niigata, Niigata 951-8566, Japan
  • Okayama University Hospital
    Okayama, Okayama-ken 700-8558, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Osaka 573-1191, Japan

Showing the first 100 of 133 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. PubMed 31666701 ↗
  • Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4. PubMed 34096690 ↗
  • Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022 Jan;23(1):115-124. doi: 10.1016/S1470-2045(21)00605-7. Epub 2021 Dec 15. PubMed 34919824 ↗
  • Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20. PubMed 32955176 ↗
  • Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 Nov;599(7886):679-683. doi: 10.1038/s41586-021-04065-2. Epub 2021 Nov 10. PubMed 34759319 ↗
  • Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023 Jun 20;41(18):3311-3317. doi: 10.1200/JCO.22.02524. Epub 2023 Apr 25. PubMed 37098232 ↗
  • Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. Future Oncol. 2024 Jan;20(3):113-120. doi: 10.2217/fon-2023-0560. Epub 2023 Nov 27. PubMed 38010044 ↗
  • Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, Feng H, Geisberg J, Wang J, Evans KE, Lyu H, Schalck A, Feng N, Lopez AM, Bristow CA, Kim MP, Rajapakshe KI, Bahrambeigi V, Roth JA, Garg K, Guerrero PA, Stanger BZ, Cristea S, Lowe SW, Baslan T, Van Allen EM, Mancias JD, Chan E, Anderson A, Katlinskaya YV, Shalek AK, Hong DS, Pant S, Hallin J, Anderes K, Olson P, Heffernan TP, Chugh S, Christensen JG, Maitra A, Wolpin BM, Raghavan S, Nowak JA, Winter PS, Dougan SK, Aguirre AJ. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 1;14(11):2135-2161. doi: 10.1158/2159-8290.CD-24-0177. PubMed 38975874 ↗
  • Hochmair MJ, Vermaelen K, Mountzios G, Carcereny E, Dooms C, Lee SH, Morocz E, Kato T, Ciuleanu TE, Dy GK, Parente B, O'Byrne KJ, Chu QS, Castro Junior G, Girard N, Snyder W, Tran Q, Kormany W, Houk B, Mehta B, Curioni-Fontecedro A. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. Eur J Cancer. 2024 Sep;208:114204. doi: 10.1016/j.ejca.2024.114204. Epub 2024 Jul 5. PubMed 39029295 ↗
  • Nagase M, Houk B, Vuu I, Cardona P, Dutta S, Lin CW. Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies. AAPS J. 2025 Jan 13;27(1):26. doi: 10.1208/s12248-024-01013-6. PubMed 39806205 ↗
  • Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023 Jan 5;388(1):33-43. doi: 10.1056/NEJMoa2208470. Epub 2022 Dec 21. PubMed 36546651 ↗
  • Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang HL, Wurz RP, Xue M, Yang KC, Achanta P, Bartberger MD, Canon J, Hollis LS, McCarter JD, Mohr C, Rex K, Saiki AY, San Miguel T, Volak LP, Wang KH, Whittington DA, Zech SG, Lipford JR, Cee VJ. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. J Med Chem. 2020 Jan 9;63(1):52-65. doi: 10.1021/acs.jmedchem.9b01180. Epub 2019 Dec 24. PubMed 31820981 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in May 2026, 93 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2018
First posted
Jul 26, 2018
StartActual
Aug 27, 2018
Primary completionActual
May 29, 2026
CompletionActual
May 29, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03600883
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Aug 27, 2018
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Jun 30, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion